25 XP   0   0   10

Heidelberg Pharma AG
Buy, Hold or Sell?

Let's analyse Heidelberg Pharma AG together

PenkeI guess you are interested in Heidelberg Pharma AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Heidelberg Pharma AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Heidelberg Pharma AG

I send you an email if I find something interesting about Heidelberg Pharma AG.

Quick analysis of Heidelberg Pharma AG (30 sec.)










What can you expect buying and holding a share of Heidelberg Pharma AG? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.06
Expected worth in 1 year
€0.69
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
€-0.37
Return On Investment
-12.5%

For what price can you sell your share?

Current Price per Share
€2.96
Expected price per share
€2.93 - €3.6
How sure are you?
50%

1. Valuation of Heidelberg Pharma AG (5 min.)




Live pricePrice per Share (EOD)

€2.96

Intrinsic Value Per Share

€-5.88 - €-4.53

Total Value Per Share

€-4.82 - €-3.47

2. Growth of Heidelberg Pharma AG (5 min.)




Is Heidelberg Pharma AG growing?

Current yearPrevious yearGrowGrow %
How rich?$52.5m$15.6m$40.7m72.3%

How much money is Heidelberg Pharma AG making?

Current yearPrevious yearGrowGrow %
Making money-$5.4m-$5.2m-$171.5k-3.2%
Net Profit Margin-214.1%-344.3%--

How much money comes from the company's main activities?

3. Financial Health of Heidelberg Pharma AG (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#472 / 1016

Most Revenue
#417 / 1016

Most Profit
#435 / 1016

Most Efficient
#647 / 1016

What can you expect buying and holding a share of Heidelberg Pharma AG? (5 min.)

Welcome investor! Heidelberg Pharma AG's management wants to use your money to grow the business. In return you get a share of Heidelberg Pharma AG.

What can you expect buying and holding a share of Heidelberg Pharma AG?

First you should know what it really means to hold a share of Heidelberg Pharma AG. And how you can make/lose money.

Speculation

The Price per Share of Heidelberg Pharma AG is €2.96. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Heidelberg Pharma AG.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Heidelberg Pharma AG, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.06. Based on the TTM, the Book Value Change Per Share is €-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is €0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Heidelberg Pharma AG.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.10-3.5%-0.02-0.8%-0.03-1.0%-0.07-2.3%-0.06-1.9%
Usd Book Value Change Per Share-0.05-1.7%-0.10-3.3%0.3712.4%0.030.9%0.020.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-1.7%-0.10-3.3%0.3712.4%0.030.9%0.020.7%
Usd Price Per Share2.94-3.97-5.99-4.84-3.68-
Price to Earnings Ratio-7.13-311.57-117.80-77.14-31.62-
Price-to-Total Gains Ratio-59.89-39.27--252.24--67.52--45.66-
Price to Book Ratio2.61-3.26--701.63--339.88--165.81-
Price-to-Total Gains Ratio-59.89-39.27--252.24--67.52--45.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.151216
Number of shares317
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.100.03
Usd Total Gains Per Share-0.100.03
Gains per Quarter (317 shares)-31.338.49
Gains per Year (317 shares)-125.3133.97
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-125-13503424
20-251-26006858
30-376-385010292
40-501-5100136126
50-627-6350170160
60-752-7600204194
70-877-8850238228
80-1002-10100272262
90-1128-11350306296
100-1253-12600340330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%4.08.00.033.3%4.016.00.020.0%5.035.00.012.5%5.055.00.08.3%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%10.030.00.025.0%16.041.03.026.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.060.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%10.030.00.025.0%16.041.03.026.7%

Fundamentals of Heidelberg Pharma AG

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-XX for the treatment of solid/hematological tumors; MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; and TAK-ATACs for oncology. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; urothelial carcinoma or bladder cancer, which is in Phase II study; and triple-negative breast cancer that is in Phase II study. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Fundamental data was last updated by Penke on 2024-04-10 06:23:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Heidelberg Pharma AG.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Heidelberg Pharma AG earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A Net Profit Margin of -139.8% means that €-1.40 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Heidelberg Pharma AG:

  • The MRQ is -139.8%. The company is making a huge loss. -2
  • The TTM is -214.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-139.8%TTM-214.1%+74.3%
TTM-214.1%YOY-344.3%+130.2%
TTM-214.1%5Y-527.3%+313.2%
5Y-527.3%10Y-481.3%-46.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-139.8%-197.2%+57.4%
TTM-214.1%-210.4%-3.7%
YOY-344.3%-279.3%-65.0%
5Y-527.3%-436.8%-90.5%
10Y-481.3%-599.3%+118.0%
1.1.2. Return on Assets

Shows how efficient Heidelberg Pharma AG is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • -6.4% Return on Assets means that Heidelberg Pharma AG generated €-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Heidelberg Pharma AG:

  • The MRQ is -6.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.4%TTM-6.5%+0.1%
TTM-6.5%YOY-15.3%+8.8%
TTM-6.5%5Y-17.1%+10.7%
5Y-17.1%10Y-14.0%-3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.4%-13.6%+7.2%
TTM-6.5%-12.9%+6.4%
YOY-15.3%-11.9%-3.4%
5Y-17.1%-14.2%-2.9%
10Y-14.0%-16.2%+2.2%
1.1.3. Return on Equity

Shows how efficient Heidelberg Pharma AG is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • -9.1% Return on Equity means Heidelberg Pharma AG generated €-0.09 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Heidelberg Pharma AG:

  • The MRQ is -9.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.1%TTM-9.6%+0.4%
TTM-9.6%YOY-2.4%-7.1%
TTM-9.6%5Y-23.5%+14.0%
5Y-23.5%10Y-19.5%-4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.1%-17.0%+7.9%
TTM-9.6%-16.1%+6.5%
YOY-2.4%-15.4%+13.0%
5Y-23.5%-20.0%-3.5%
10Y-19.5%-21.1%+1.6%

1.2. Operating Efficiency of Heidelberg Pharma AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Heidelberg Pharma AG is operating .

  • Measures how much profit Heidelberg Pharma AG makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Heidelberg Pharma AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-180.2%+180.2%
TTM-180.2%YOY-338.2%+157.9%
TTM-180.2%5Y-513.3%+333.0%
5Y-513.3%10Y-472.5%-40.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-180.2%-224.4%+44.2%
YOY-338.2%-288.4%-49.8%
5Y-513.3%-475.2%-38.1%
10Y-472.5%-624.7%+152.2%
1.2.2. Operating Ratio

Measures how efficient Heidelberg Pharma AG is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.52 means that the operating costs are €2.52 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 2.523. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.009. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.523TTM4.009-1.486
TTM4.009YOY4.424-0.415
TTM4.0095Y6.466-2.457
5Y6.46610Y6.049+0.417
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5232.997-0.474
TTM4.0093.247+0.762
YOY4.4243.766+0.658
5Y6.4665.675+0.791
10Y6.0497.857-1.808

1.3. Liquidity of Heidelberg Pharma AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Heidelberg Pharma AG is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.86 means the company has €2.86 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 2.864. The company is able to pay all its short-term debts. +1
  • The TTM is 3.016. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.864TTM3.016-0.152
TTM3.016YOY1.221+1.795
TTM3.0165Y1.820+1.196
5Y1.82010Y2.081-0.261
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8643.930-1.066
TTM3.0164.251-1.235
YOY1.2215.436-4.215
5Y1.8206.045-4.225
10Y2.0816.363-4.282
1.3.2. Quick Ratio

Measures if Heidelberg Pharma AG is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A Quick Ratio of 0.05 means the company can pay off €0.05 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 0.050. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 2.058. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.050TTM2.058-2.009
TTM2.058YOY1.088+0.970
TTM2.0585Y1.517+0.541
5Y1.51710Y1.837-0.321
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0503.629-3.579
TTM2.0584.065-2.007
YOY1.0885.397-4.309
5Y1.5175.993-4.476
10Y1.8376.277-4.440

1.4. Solvency of Heidelberg Pharma AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Heidelberg Pharma AG assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Heidelberg Pharma AG to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30 means that Heidelberg Pharma AG assets are financed with 29.9% credit (debt) and the remaining percentage (100% - 29.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 0.299. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.314. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.299TTM0.314-0.016
TTM0.314YOY0.901-0.587
TTM0.3145Y0.492-0.177
5Y0.49210Y0.362+0.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2990.332-0.033
TTM0.3140.334-0.020
YOY0.9010.268+0.633
5Y0.4920.366+0.126
10Y0.3620.390-0.028
1.4.2. Debt to Equity Ratio

Measures if Heidelberg Pharma AG is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A Debt to Equity ratio of 42.6% means that company has €0.43 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 0.426. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.460. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.426TTM0.460-0.034
TTM0.460YOY0.127+0.332
TTM0.4605Y0.515-0.056
5Y0.51510Y0.427+0.088
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4260.381+0.045
TTM0.4600.390+0.070
YOY0.1270.334-0.207
5Y0.5150.434+0.081
10Y0.4270.466-0.039

2. Market Valuation of Heidelberg Pharma AG

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Heidelberg Pharma AG generates.

  • Above 15 is considered overpriced but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A PE ratio of -7.13 means the investor is paying €-7.13 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Heidelberg Pharma AG:

  • The EOD is -7.650. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.133. Based on the earnings, the company is expensive. -2
  • The TTM is 311.567. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.650MRQ-7.133-0.517
MRQ-7.133TTM311.567-318.701
TTM311.567YOY117.801+193.767
TTM311.5675Y77.135+234.432
5Y77.13510Y31.619+45.516
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.650-2.315-5.335
MRQ-7.133-2.560-4.573
TTM311.567-2.664+314.231
YOY117.801-4.122+121.923
5Y77.135-6.258+83.393
10Y31.619-6.108+37.727
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Heidelberg Pharma AG:

  • The EOD is -4.775. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.452. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.003. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.775MRQ-4.452-0.323
MRQ-4.452TTM-5.003+0.550
TTM-5.003YOY-15.840+10.838
TTM-5.0035Y-14.572+9.570
5Y-14.57210Y-20.181+5.609
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.775-3.067-1.708
MRQ-4.452-3.251-1.201
TTM-5.003-3.545-1.458
YOY-15.840-5.595-10.245
5Y-14.572-8.315-6.257
10Y-20.181-8.708-11.473
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Heidelberg Pharma AG is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.61 means the investor is paying €2.61 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Heidelberg Pharma AG:

  • The EOD is 2.796. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.607. Based on the equity, the company is underpriced. +1
  • The TTM is 3.256. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.796MRQ2.607+0.189
MRQ2.607TTM3.256-0.649
TTM3.256YOY-701.630+704.886
TTM3.2565Y-339.881+343.137
5Y-339.88110Y-165.813-174.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7961.905+0.891
MRQ2.6072.111+0.496
TTM3.2562.095+1.161
YOY-701.6302.836-704.466
5Y-339.8813.443-343.324
10Y-165.8133.794-169.607
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Heidelberg Pharma AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.046-0.093+101%0.346-113%0.025-283%0.018-350%
Book Value Per Share--1.0591.135-7%0.338+213%0.476+123%0.413+156%
Current Ratio--2.8643.016-5%1.221+135%1.820+57%2.081+38%
Debt To Asset Ratio--0.2990.314-5%0.901-67%0.492-39%0.362-17%
Debt To Equity Ratio--0.4260.460-7%0.127+235%0.515-17%0.4270%
Dividend Per Share----0%-0%-0%-0%
Eps---0.097-0.022-77%-0.027-72%-0.063-35%-0.054-44%
Free Cash Flow Per Share---0.155-0.185+20%0.004-3864%-0.092-41%-0.066-57%
Free Cash Flow To Equity Per Share---0.155-0.239+54%0.437-135%0.031-605%0.021-842%
Gross Profit Margin--1.000-1.664+266%1.021-2%0.471+112%0.736+36%
Intrinsic Value_10Y_max---4.533--------
Intrinsic Value_10Y_min---5.878--------
Intrinsic Value_1Y_max---0.293--------
Intrinsic Value_1Y_min---0.440--------
Intrinsic Value_3Y_max---1.004--------
Intrinsic Value_3Y_min---1.458--------
Intrinsic Value_5Y_max---1.862--------
Intrinsic Value_5Y_min---2.619--------
Market Cap137950800.000+7%128629800.000173939867.745-26%558994987.500-77%297216166.049-57%203677716.150-37%
Net Profit Margin---1.398-2.141+53%-3.443+146%-5.273+277%-4.813+244%
Operating Margin----1.8020%-3.3820%-5.1330%-4.7250%
Operating Ratio--2.5234.009-37%4.424-43%6.466-61%6.049-58%
Pb Ratio2.796+7%2.6073.256-20%-701.630+27013%-339.881+13137%-165.813+6460%
Pe Ratio-7.650-7%-7.133311.567-102%117.801-106%77.135-109%31.619-123%
Price Per Share2.960+7%2.7603.725-26%5.625-51%4.548-39%3.456-20%
Price To Free Cash Flow Ratio-4.775-7%-4.452-5.003+12%-15.840+256%-14.572+227%-20.181+353%
Price To Total Gains Ratio-64.225-7%-59.88639.271-252%-252.244+321%-67.515+13%-45.661-24%
Quick Ratio--0.0502.058-98%1.088-95%1.517-97%1.837-97%
Return On Assets---0.064-0.065+1%-0.153+138%-0.171+167%-0.140+119%
Return On Equity---0.091-0.096+5%-0.024-73%-0.235+157%-0.195+114%
Total Gains Per Share---0.046-0.093+101%0.346-113%0.025-283%0.018-350%
Usd Book Value--52527146.82256392637.295-7%15604607.381+237%23623302.599+122%20504366.975+156%
Usd Book Value Change Per Share---0.049-0.099+101%0.368-113%0.027-283%0.020-350%
Usd Book Value Per Share--1.1271.208-7%0.360+213%0.506+123%0.440+156%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.103-0.024-77%-0.029-72%-0.067-35%-0.057-44%
Usd Free Cash Flow---7689514.244-9217214.446+20%-2522270.281-67%-5370542.800-30%-3702813.605-52%
Usd Free Cash Flow Per Share---0.165-0.197+20%0.004-3864%-0.098-41%-0.071-57%
Usd Free Cash Flow To Equity Per Share---0.165-0.254+54%0.465-135%0.033-605%0.022-842%
Usd Market Cap146862421.680+7%136939285.080185176383.201-26%595106063.693-77%316416330.376-57%216835296.613-37%
Usd Price Per Share3.151+7%2.9383.966-26%5.988-51%4.842-39%3.679-20%
Usd Profit---4799364.779-5415216.983+13%-5243712.850+9%-5041118.193+5%-3619345.505-25%
Usd Revenue--3432542.9382623949.429+31%4927501.100-30%2444304.513+40%1563084.897+120%
Usd Total Gains Per Share---0.049-0.099+101%0.368-113%0.027-283%0.020-350%
 EOD+5 -3MRQTTM+21 -12YOY+12 -215Y+16 -1710Y+14 -19

3.2. Fundamental Score

Let's check the fundamental score of Heidelberg Pharma AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.650
Price to Book Ratio (EOD)Between0-12.796
Net Profit Margin (MRQ)Greater than0-1.398
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.050
Current Ratio (MRQ)Greater than12.864
Debt to Asset Ratio (MRQ)Less than10.299
Debt to Equity Ratio (MRQ)Less than10.426
Return on Equity (MRQ)Greater than0.15-0.091
Return on Assets (MRQ)Greater than0.05-0.064
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Heidelberg Pharma AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.198
Ma 20Greater thanMa 503.048
Ma 50Greater thanMa 1003.073
Ma 100Greater thanMa 2003.218
OpenGreater thanClose3.000
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-11-302023-02-282023-05-312023-08-312023-11-30
Long-term Assets Other  62935035035-36-1
Tax Provision  38417919982100-377-277



Latest Balance Sheet

Balance Sheet of 2023-11-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets70,353
Total Liabilities21,013
Total Stockholder Equity49,340
 As reported
Total Liabilities 21,013
Total Stockholder Equity+ 49,340
Total Assets = 70,353

Assets

Total Assets70,353
Total Current Assets56,634
Long-term Assets13,719
Total Current Assets
Cash And Cash Equivalents 43,439
Net Receivables 979
Inventory 9,957
Total Current Assets  (as reported)56,634
Total Current Assets  (calculated)54,375
+/- 2,259
Long-term Assets
Property Plant Equipment 3,877
Goodwill 6,111
Intangible Assets 2,787
Long-term Assets  (as reported)13,719
Long-term Assets  (calculated)12,775
+/- 944

Liabilities & Shareholders' Equity

Total Current Liabilities19,775
Long-term Liabilities1,239
Total Stockholder Equity49,340
Total Current Liabilities
Short Long Term Debt 5,648
Accounts payable 7,875
Total Current Liabilities  (as reported)19,775
Total Current Liabilities  (calculated)13,523
+/- 6,252
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt184
Long-term Liabilities Other 1
Long-term Liabilities  (as reported)1,239
Long-term Liabilities  (calculated)184
+/- 1,055
Total Stockholder Equity
Total Stockholder Equity (as reported)49,340
Total Stockholder Equity (calculated)0
+/- 49,340
Other
Capital Stock46,605
Common Stock Shares Outstanding 46,605
Net Invested Capital 54,988
Net Working Capital 36,859
Property Plant and Equipment Gross 10,941



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-05-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-312010-05-312010-02-282009-11-302009-08-312009-05-312009-02-28
> Total Assets 
0
0
0
12,013
14,001
6,747
10,994
5,591
8,270
28,125
24,046
20,814
26,326
22,414
43,174
37,721
32,532
27,983
24,917
22,311
18,969
16,574
16,125
15,030
13,994
17,139
15,427
12,102
13,028
15,948
13,937
15,241
13,304
16,188
15,112
41,490
38,064
36,900
34,881
31,192
28,326
26,968
25,912
22,991
19,026
29,075
25,398
19,609
17,541
15,691
28,547
21,732
20,652
33,937
29,805
100,582
86,476
77,965
74,328
70,353
70,35374,32877,96586,476100,58229,80533,93720,65221,73228,54715,69117,54119,60925,39829,07519,02622,99125,91226,96828,32631,19234,88136,90038,06441,49015,11216,18813,30415,24113,93715,94813,02812,10215,42717,13913,99415,03016,12516,57418,96922,31124,91727,98332,53237,72143,17422,41426,32620,81424,04628,1258,2705,59110,9946,74714,00112,013000
   > Total Current Assets 
0
0
0
10,134
12,174
4,792
9,084
3,399
6,134
15,573
11,321
7,997
13,644
9,711
30,503
25,189
20,138
15,697
12,959
9,506
6,240
3,847
3,402
2,910
1,849
5,043
3,426
2,069
3,082
5,834
3,743
4,990
3,134
5,983
4,837
31,209
27,705
25,983
23,992
20,289
17,119
15,701
14,566
11,594
7,343
16,973
13,109
7,521
5,208
3,073
15,859
9,013
8,041
21,439
17,267
87,880
73,673
64,887
61,373
56,634
56,63461,37364,88773,67387,88017,26721,4398,0419,01315,8593,0735,2087,52113,10916,9737,34311,59414,56615,70117,11920,28923,99225,98327,70531,2094,8375,9833,1344,9903,7435,8343,0822,0693,4265,0431,8492,9103,4023,8476,2409,50612,95915,69720,13825,18930,5039,71113,6447,99711,32115,5736,1343,3999,0844,79212,17410,134000
       Cash And Cash Equivalents 
0
0
0
3,411
10,659
3,309
7,762
1,943
4,624
13,516
8,073
3,421
7,883
2,920
28,677
23,363
17,675
12,894
9,876
8,920
5,546
2,832
2,821
2,197
1,369
4,101
3,068
1,306
2,305
5,142
3,269
4,574
2,568
5,504
4,491
30,381
27,151
25,535
22,709
19,440
16,069
13,109
12,709
9,884
4,903
15,129
9,226
4,982
2,915
930
13,598
6,141
4,515
18,017
10,523
81,329
65,011
57,379
50,675
43,439
43,43950,67557,37965,01181,32910,52318,0174,5156,14113,5989302,9154,9829,22615,1294,9039,88412,70913,10916,06919,44022,70925,53527,15130,3814,4915,5042,5684,5743,2695,1422,3051,3063,0684,1011,3692,1972,8212,8325,5468,9209,87612,89417,67523,36328,6772,9207,8833,4218,07313,5164,6241,9437,7623,30910,6593,411000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
747
1,409
1,421
1,126
3,454
1,510
1,434
1,302
1,151
1,449
1,140
1,506
1,903
1,452
2,595
1,380
1,060
979
9791,0601,3802,5951,4521,9031,5061,1401,4491,1511,3021,4341,5103,4541,1261,4211,409747000000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
6,689
1,481
1,449
1,287
1,290
1,366
1,809
3,017
4,061
5,242
6,429
1,533
1,567
2,245
2,571
2,955
509
645
964
553
524
345
741
117
484
466
421
218
225
319
336
169
649
473
307
1,237
671
1,001
2,552
1,825
1,473
1,597
1,261
3,575
2,309
1,718
1,545
1,454
2,126
2,249
2,365
2,514
513
808
914
744
0
07449148085132,5142,3652,2492,1261,4541,5451,7182,3093,5751,2611,5971,4731,8252,5521,0016711,2373074736491693363192252184214664841177413455245539646455092,9552,5712,2451,5671,5336,4295,2424,0613,0171,8091,3661,2901,2871,4491,4816,689000
   > Long-term Assets 
0
0
0
1,879
1,827
1,955
1,911
2,192
2,137
12,552
12,724
12,818
12,682
12,702
12,671
12,532
12,394
12,285
11,958
12,805
12,729
12,727
12,724
12,120
12,145
12,096
12,001
10,033
9,946
10,114
10,194
10,252
10,170
10,205
10,275
10,281
10,359
10,917
10,889
10,903
11,207
11,267
11,346
11,396
11,683
12,102
12,289
12,088
12,333
12,618
12,688
12,719
12,611
12,498
12,537
12,702
12,803
13,078
12,955
13,719
13,71912,95513,07812,80312,70212,53712,49812,61112,71912,68812,61812,33312,08812,28912,10211,68311,39611,34611,26711,20710,90310,88910,91710,35910,28110,27510,20510,17010,25210,19410,1149,94610,03312,00112,09612,14512,12012,72412,72712,72912,80511,95812,28512,39412,53212,67112,70212,68212,81812,72412,5522,1372,1921,9111,9551,8271,879000
       Property Plant Equipment 
0
0
0
424
405
567
552
864
834
1,686
1,947
2,074
2,061
2,135
2,154
2,087
2,011
1,945
1,677
1,345
1,300
1,308
1,255
1,062
1,004
936
905
1,004
951
1,129
1,182
1,278
1,192
1,212
1,290
1,329
1,381
1,741
1,729
1,970
2,231
2,286
2,385
2,457
2,729
3,151
3,314
3,144
3,308
3,564
3,621
3,694
3,577
3,488
3,548
3,747
3,832
4,123
4,012
3,877
3,8774,0124,1233,8323,7473,5483,4883,5773,6943,6213,5643,3083,1443,3143,1512,7292,4572,3852,2862,2311,9701,7291,7411,3811,3291,2901,2121,1921,2781,1821,1299511,0049059361,0041,0621,2551,3081,3001,3451,6771,9452,0112,0872,1542,1352,0612,0741,9471,686834864552567405424000
       Goodwill 
0
0
0
0
0
0
0
0
0
8,924
8,924
6,111
6,111
6,111
0
0
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,111006,1116,1116,1118,9248,924000000000
       Intangible Assets 
0
0
0
1,294
1,261
1,227
1,197
1,166
1,141
1,779
1,690
4,356
4,248
4,194
0
0
4,045
4,001
3,933
3,074
3,037
3,007
2,977
2,949
2,928
2,913
2,899
2,869
2,859
2,849
2,869
2,841
2,835
2,831
2,823
2,820
2,815
2,942
2,922
2,801
2,823
2,828
2,808
2,801
2,786
2,783
2,807
2,818
2,869
2,898
2,911
2,901
2,887
2,864
2,843
2,838
2,824
2,809
2,796
2,787
2,7872,7962,8092,8242,8382,8432,8642,8872,9012,9112,8982,8692,8182,8072,7832,7862,8012,8082,8282,8232,8012,9222,9422,8152,8202,8232,8312,8352,8412,8692,8492,8592,8692,8992,9132,9282,9492,9773,0073,0373,0743,9334,0014,045004,1944,2484,3561,6901,7791,1411,1661,1971,2271,2611,294000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45
45
45
45
45
45
45
45
35
35
35
35
0
0
0
35
0
0350003535353545454545454545450000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
8,968
7,604
6,605
6,464
6,886
15,483
29,105
27,760
25,337
23,459
22,695
21,724
17,800
14,565
11,543
8,875
7,362
6,884
6,005
2,963
3,154
3,180
3,010
2,938
2,622
2,150
2,253
1,946
5,485
5,481
5,649
7,904
4,466
3,422
4,345
4,872
5,306
5,410
5,390
5,330
6,697
7,127
7,545
6,794
6,730
10,913
15,765
14,799
15,033
21,016
35,513
35,878
33,938
26,311
27,074
22,840
21,013
21,01322,84027,07426,31133,93835,87835,51321,01615,03314,79915,76510,9136,7306,7947,5457,1276,6975,3305,3905,4105,3064,8724,3453,4224,4667,9045,6495,4815,4851,9462,2532,1502,6222,9383,0103,1803,1542,9636,0056,8847,3628,87511,54314,56517,80021,72422,69523,45925,33727,76029,10515,4836,8866,4646,6057,6048,968000
   > Total Current Liabilities 
0
0
0
8,351
7,109
6,105
6,082
6,504
15,267
21,705
21,045
20,205
19,671
20,074
18,751
16,739
14,332
11,351
8,754
7,285
6,820
5,992
2,956
3,152
3,180
3,010
2,938
2,616
2,145
2,248
1,941
5,478
5,474
5,642
7,897
4,457
3,414
4,337
4,863
5,306
5,410
5,390
5,330
6,462
6,879
7,351
6,643
6,628
10,833
15,709
14,672
14,935
20,961
27,995
29,401
27,934
21,496
23,475
20,406
19,775
19,77520,40623,47521,49627,93429,40127,99520,96114,93514,67215,70910,8336,6286,6437,3516,8796,4625,3305,3905,4105,3064,8634,3373,4144,4577,8975,6425,4745,4781,9412,2482,1452,6162,9383,0103,1803,1522,9565,9926,8207,2858,75411,35114,33216,73918,75120,07419,67120,20521,04521,70515,2676,5046,0826,1057,1098,351000
       Short-term Debt 
0
0
0
0
0
58
58
58
58
138
220
10,800
10,488
10,599
278
2,848
2,710
2,734
2,741
2,728
2,585
2,623
67
77
13
7
1
0
0
0
0
3,748
3,767
886
3,879
0
0
0
0
0
0
0
0
0
94
96
98
101
99
96
94
10,556
89
93
87
15,880
90
111
5,659
0
05,6591119015,88087938910,5569496991019896940000000003,8798863,7673,7480000171377672,6232,5852,7282,7412,7342,7102,84827810,59910,48810,8002201385858585800000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,465
0
4,364
0
15,786
0
10,399
5,548
5,648
5,6485,54810,399015,78604,364010,465000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
2,099
2,451
1,955
1,930
2,040
1,408
1,953
2,824
1,412
1,502
1,624
1,631
904
493
714
493
191
504
515
171
277
151
296
224
279
333
466
310
132
635
525
661
1,501
637
238
989
405
1,181
954
474
1,012
1,783
1,815
2,053
2,812
2,604
1,555
1,108
903
1,237
2,585
4,606
3,051
1,947
3,482
3,967
7,875
7,8753,9673,4821,9473,0514,6062,5851,2379031,1081,5552,6042,8122,0531,8151,7831,0124749541,1814059892386371,5016615256351323104663332792242961512771715155041914937144939041,6311,6241,5021,4122,8241,9531,4082,0401,9301,9552,4512,099000
       Other Current Liabilities 
0
0
0
6,252
4,658
4,092
4,094
4,406
13,801
19,614
18,000
7,993
7,681
7,851
16,842
12,987
11,129
7,903
5,520
4,366
3,730
2,854
2,718
2,798
3,016
2,708
2,714
2,337
1,811
1,782
1,630
1,598
1,071
4,231
3,357
2,956
2,777
4,098
3,874
4,900
4,228
4,436
4,856
5,450
5,002
5,441
4,492
3,715
8,131
14,057
13,469
3,206
19,636
25,317
24,708
3,986
14,720
15,148
6,108
0
06,10815,14814,7203,98624,70825,31719,6363,20613,46914,0578,1313,7154,4925,4415,0025,4504,8564,4364,2284,9003,8744,0982,7772,9563,3574,2311,0711,5981,6301,7821,8112,3372,7142,7083,0162,7982,7182,8543,7304,3665,5207,90311,12912,98716,8427,8517,6817,99318,00019,61413,8014,4064,0944,0924,6586,252000
   > Long-term Liabilities 
0
0
0
617
495
500
382
382
215
7,401
6,715
5,132
3,788
2,621
2,973
1,061
233
193
121
77
64
13
7
2
0
0
0
6
5
5
5
7
7
7
7
9
9
9
9
0
0
0
0
235
248
193
151
102
79
57
128
98
55
7,518
6,477
6,003
4,815
3,599
2,435
1,239
1,2392,4353,5994,8156,0036,4777,518559812857791021511932482350000999977775556000271364771211932331,0612,9732,6213,7885,1326,7157,401215382382500495617000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
235
85
55
25
0
0
0
94
23
0
7,466
6,377
0
4,735
0
2,335
0
02,33504,73506,3777,466023940002555852350000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
3,045
6,397
142
4,530
-1,295
-7,212
-980
-3,714
-4,523
2,867
-281
21,449
19,921
17,968
16,439
16,043
14,950
12,085
10,569
13,162
11,876
10,813
14,129
12,489
9,480
10,879
13,695
11,991
9,756
7,823
10,539
7,208
37,024
34,641
32,555
30,009
25,886
22,916
21,578
20,582
16,293
11,899
21,530
18,604
12,879
6,628
-74
13,747
6,699
-365
-1,576
-6,073
66,644
60,165
50,891
51,488
49,340
49,34051,48850,89160,16566,644-6,073-1,576-3656,69913,747-746,62812,87918,60421,53011,89916,29320,58221,57822,91625,88630,00932,55534,64137,0247,20810,5397,8239,75611,99113,69510,8799,48012,48914,12910,81311,87613,16210,56912,08514,95016,04316,43917,96819,92121,449-2812,867-4,523-3,714-980-7,212-1,2954,5301426,3973,045000
   Common Stock
0
0
0
13,781
15,958
15,958
18,413
18,413
18,413
21,613
21,613
21,613
24,815
24,815
31,276
31,276
31,276
31,276
31,276
31,276
31,276
31,276
7,819
7,819
7,819
9,306
9,306
9,306
10,679
12,928
12,928
12,928
12,928
14,968
14,968
22,453
28,103
28,130
28,130
28,133
28,144
28,156
28,158
28,210
28,210
31,031
31,047
31,062
31,062
31,066
34,173
34,176
34,176
34,176
34,176
46,584
46,584
46,600
46,605
0
046,60546,60046,58446,58434,17634,17634,17634,17634,17331,06631,06231,06231,04731,03128,21028,21028,15828,15628,14428,13328,13028,13028,10322,45314,96814,96812,92812,92812,92812,92810,6799,3069,3069,3067,8197,8197,81931,27631,27631,27631,27631,27631,27631,27631,27624,81524,81521,61321,61321,61318,41318,41318,41315,95815,95813,781000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000-4,880000-4,190000-3,705000-3,357000-3,036000-2,748000-2,848000-2,482000-1,8780000000-1,2930000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
113,368
119,943
119,844
127,443
128,787
127,531
135,230
135,105
134,993
141,735
141,642
158,722
161,042
159,189
159,223
159,242
161,763
159,300
159,291
182,761
188,213
185,377
188,027
188,039
190,782
189,139
191,013
191,045
194,113
191,109
194,078
194,107
223,147
214,171
214,356
214,515
218,348
214,747
214,788
215,109
219,458
215,445
227,107
227,210
232,251
227,441
227,503
243,980
244,215
244,398
244,546
244,668
311,454
311,538
311,637
312,116
0
0312,116311,637311,538311,454244,668244,546244,398244,215243,980227,503227,441232,251227,210227,107215,445219,458215,109214,788214,747218,348214,515214,356214,171223,147194,107194,078191,109194,113191,045191,013189,139190,782188,039188,027185,377188,213182,761159,291159,300161,763159,242159,223159,189161,042158,722141,642141,735134,993135,105135,230127,531128,787127,443119,844119,943113,368000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-11-30)

Gross Profit (+$)
totalRevenue9,859
Cost of Revenue-3,253
Gross Profit6,6066,606
 
Operating Income (+$)
Gross Profit6,606
Operating Expense-37,956
Operating Income-28,097-31,350
 
Operating Expense (+$)
Research Development28,075
Selling General Administrative5,248
Selling And Marketing Expenses0
Operating Expense37,95633,323
 
Net Interest Income (+$)
Interest Income1,625
Interest Expense-762
Other Finance Cost-0
Net Interest Income863
 
Pretax Income (+$)
Operating Income-28,097
Net Interest Income863
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,346-28,097
EBIT - interestExpense = -762
-20,346
-19,585
Interest Expense762
Earnings Before Interest and Taxes (EBIT)0-19,585
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-20,346
Tax Provision-0
Net Income From Continuing Ops-20,346-20,346
Net Income-20,346
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-863
 

Technical Analysis of Heidelberg Pharma AG
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Heidelberg Pharma AG. The general trend of Heidelberg Pharma AG is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Heidelberg Pharma AG's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Heidelberg Pharma AG.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.25 < 3.31 < 3.6.

The bearish price targets are: 2.96 > 2.96 > 2.93.

Tweet this
Heidelberg Pharma AG Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Heidelberg Pharma AG. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Heidelberg Pharma AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Heidelberg Pharma AG. The current macd is -0.02712414.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Heidelberg Pharma AG price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Heidelberg Pharma AG. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Heidelberg Pharma AG price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Heidelberg Pharma AG Daily Moving Average Convergence/Divergence (MACD) ChartHeidelberg Pharma AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Heidelberg Pharma AG. The current adx is 11.00.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Heidelberg Pharma AG shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Heidelberg Pharma AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Heidelberg Pharma AG. The current sar is 2.88484288.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Heidelberg Pharma AG Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Heidelberg Pharma AG. The current rsi is 37.20. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Heidelberg Pharma AG Daily Relative Strength Index (RSI) ChartHeidelberg Pharma AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Heidelberg Pharma AG. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Heidelberg Pharma AG price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Heidelberg Pharma AG Daily Stochastic Oscillator ChartHeidelberg Pharma AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Heidelberg Pharma AG. The current cci is -146.17829068.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Heidelberg Pharma AG Daily Commodity Channel Index (CCI) ChartHeidelberg Pharma AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Heidelberg Pharma AG. The current cmo is -37.05671214.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Heidelberg Pharma AG Daily Chande Momentum Oscillator (CMO) ChartHeidelberg Pharma AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Heidelberg Pharma AG. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Heidelberg Pharma AG Daily Williams %R ChartHeidelberg Pharma AG Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Heidelberg Pharma AG.

Heidelberg Pharma AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Heidelberg Pharma AG. The current atr is 0.07020924.

Heidelberg Pharma AG Daily Average True Range (ATR) ChartHeidelberg Pharma AG Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Heidelberg Pharma AG. The current obv is 339,963.

Heidelberg Pharma AG Daily On-Balance Volume (OBV) ChartHeidelberg Pharma AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Heidelberg Pharma AG. The current mfi is 13.94.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Heidelberg Pharma AG Daily Money Flow Index (MFI) ChartHeidelberg Pharma AG Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Heidelberg Pharma AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Heidelberg Pharma AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Heidelberg Pharma AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.198
Ma 20Greater thanMa 503.048
Ma 50Greater thanMa 1003.073
Ma 100Greater thanMa 2003.218
OpenGreater thanClose3.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Heidelberg Pharma AG with someone you think should read this too:
  • Are you bullish or bearish on Heidelberg Pharma AG? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Heidelberg Pharma AG? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Heidelberg Pharma AG

I send you an email if I find something interesting about Heidelberg Pharma AG.


Comments

How you think about this?

Leave a comment

Stay informed about Heidelberg Pharma AG.

Receive notifications about Heidelberg Pharma AG in your mailbox!